MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-06-2026
Canopy Growth Corporation Total Non Current Liabilities 2011-2026 | CGC
Quarterly Total Non Current Liabilities Canopy Growth Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 98.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 98.3 M | 98.3 M | 98.3 M |
Total Non Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
134 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
316 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
6.61 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M |  Irlanda |
 |
Aurora Cannabis
ACB
|
681 M | $ 3.47 | 0.92 % | $ 86.3 M | Canada |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
Assertio Holdings
ASRT
|
115 M | $ 19.37 | 0.83 % | $ 124 M | USA |
 |
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | USA |
 |
Bausch Health Companies
BHC
|
26.5 B | $ 5.38 | 0.56 % | $ 1.96 B | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
23.9 M | $ 3.2 | 1.03 % | $ 45 M | USA |
 |
Cronos Group
CRON
|
10.7 M | $ 2.56 | 1.1 % | $ 1.35 B | Canada |
 |
Emergent BioSolutions
EBS
|
1.02 B | $ 8.23 | - | $ 421 M | USA |
 |
Evolus
EOLS
|
102 M | $ 4.14 | 2.61 % | $ 267 M | USA |
 |
Harrow Health
HROW
|
19.8 M | $ 35.5 | 0.54 % | $ 1.3 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | USA |
 |
OrganiGram Holdings
OGI
|
107 M | $ 1.4 | 1.63 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
105 M | $ 2.3 | 2.68 % | $ 303 M | USA |
 |
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | USA |
 |
Pacira BioSciences
PCRX
|
368 M | $ 22.49 | -0.93 % | $ 1.04 B | USA |
 |
PLx Pharma
PLXP
|
34 M | - | -27.8 % | $ 2.56 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 6.93 | -0.86 % | $ 274 M | USA |
 |
Rockwell Medical
RMTI
|
11.6 M | $ 0.95 | -0.73 % | $ 34.2 M | USA |
 |
SCYNEXIS
SCYX
|
53.4 M | $ 0.94 | 5.86 % | $ 46.9 M | USA |
 |
ProPhase Labs
PRPH
|
7.94 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | USA |
 |
Solid Biosciences
SLDB
|
19.1 M | $ 7.74 | 3.34 % | $ 677 M | USA |
 |
Sundial Growers
SNDL
|
1.03 M | $ 1.36 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 2.36 | -0.42 % | $ 2.93 M | USA |
 |
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tilray
TLRY
|
570 M | $ 6.61 | 0.84 % | $ 4.08 B | Canada |
 |
Veru
VERU
|
6.71 M | $ 2.34 | 2.18 % | $ 316 M | USA |
 |
Viatris
VTRS
|
13.8 B | $ 13.36 | -0.6 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
2.49 M | $ 0.72 | -1.17 % | $ 3.11 M | USA |
 |
Zomedica Corp.
ZOM
|
275 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
110 K | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
13.2 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
1.71 M | $ 0.61 | -3.16 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
246 M | $ 2.08 | 4.0 % | $ 24.1 M | USA |